Welcome to the second EASL HCC Summit to take place in Geneva, Switzerland from 2-5 February 2017.
Help us to inform the liver community by sharing the information provided in the HCC Summit promotional toolkit below.
Our first summit, 2 years ago, was a great success, reaching out to both scientists and clinicians with an interest in liver cancer. Following a similar winning formula, we have created a broad and exciting programme, which we hope will be both informative and stimulating.
Our Basic Science programme, 2-3 February 2017, will be centred around ‘The Hallmarks of Cancer’, including talks from eminent scientists in the cancer field, but with a focus on those translational advances most relevant to patients with primary liver cancer.
On 4-5 February an outstanding Clinical programme will take place with state-of-the-art talks on the most up to date management of our patients with liver cancer. Aimed at a wider audience, we have no doubt that there will be something for everyone. Participants will be offered the option to attend either programmes or both. There will also be the opportunity to submit abstracts of ongoing research. Some of these will be included in the oral programme, while others will be accepted as e-posters.
Participants will be offered the option to attend either programmes or both. There will also be the opportunity to submit abstracts of ongoing research. Some of these will be included in the oral programme, while others will be accepted as e-posters. We anticipate that this combination of high-quality presentations from eminent scientists and clinicians will bring together leading researchers and young investigators with an interest in liver cancer, for a highly interactive and memorable meeting.
Physicians with interest in liver cancer
Basic and translational scientists
Young researchers and trainees
Basic Science Sessions: Next generation and exome sequencing, Molecular signaling and imaging, Angiogenesis, Cell metabolism, Cell death, Inflammation, Gut microbiome, Genomic instability.
Clinical Sessions: Patient management, Epidemiology, Diagnostic challenges, Surgical and locoregional therapy, Intrahepatic cholangiocarcinoma, Systemic Treatments, Immunotherapy.
The EASL HCC Summit will provide opportunities to showcase latest developments, techniques, and drugs in HCC and enable delegates to learn more about this rapidly evolving field. Opportunities for discussion and networking will be provided throughout the course of the event.
Abstract submitters are permitted to submit the same research for presentation at the HCC Summit and The International Liver Congress™ 2017. If your work is selected for both EASL meetings you will be asked to present both in Geneva and Amsterdam.
Revisit the HCC Summit 2014 to find out what this event is all about:
In 2014, EASL welcomed over 700 people at the HCC Summit in Geneva, Switzerland over the course of 4 days. The conference combined both the basic science and clinical science aspects of liver cancer, covering aspects such as treatment and management of cancer.
CORPORATE RELATIONS & ASSOCIATION’S PROJECTS MANAGER
Tel: +41 (0) 22 807 03 69
Mob: +41 (0) 79 870 28 25
Fax: +41 (0) 22 328 07 24
CORPORATE RELATIONS & EXHIBITION COORDINATOR
Tel: +41 (0) 22 807 03 68
Fax: +41 (0) 22 328 07 24
European Association for the Study of the Liver
Tom Luedde, (Germany)
Helen Reeves, (United Kingdom)
Alejandro Forner, (Spain)
Franco Trevisani, (Italy)
NOTE: Abstract submitters are entitled to submit the same research for presentation at the HCC Summit and The International Liver Congress™ 2017. If your work is selected for both EASL meetings you will be asked to present both in Geneva and Amsterdam.